Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512063 | 0.83 | ALOX5 (0.50) | ALOX5ELANEF2CTSGHSP90AA1 | |
| SCHEMBL4313901 | 0.80 | ALOX5 (0.50) | ALOX5ELANEF2CTSGHSP90AA1 | |
| SCHEMBL6706457 | 0.79 | KDM4E (0.52) | ALOX5ELANEF2CTSGALOX15 | |
| SCHEMBL20307373 | 0.78 | ALOX15 (0.49) | ELANEALOX15L3MBTL1 | |
| SCHEMBL5801725 | 0.76 | ALOX5 (0.56) | ALOX5ELANEF2CTSG | |
| SCHEMBL343656 | 0.76 | ALOX5 (0.59) | ALOX5ELANEF2HSD17B3 | |
| SCHEMBL24610454 | 0.74 | KEAP1 (0.49) | ELANEALOX15L3MBTL1 | |
| SCHEMBL30297719 | 0.72 | ALOX5 (0.54) | ALOX5ELANEF2CTSGALOX15 | |
| SCHEMBL5098595 | 0.72 | PPARA (0.45) | ALOX5ELANEF2CTSG | |
| SCHEMBL11069881 | 0.71 | ALOX15 (0.51) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010060479-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-06-03 | — | — | WO | disclosed |